Activity of tigecycline against Streptococcus pneumoniae, an important causative pathogen of community-acquired pneumonia (CAP)

References 

1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious diseases society of America; American thoracic society. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical Infectious Diseases. 2007;44:S27–S72
2. Tygacil product monograph. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021821s013s017s018lbl.pdf2009;
3. Clinical Laboratory Standards Institute . Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—seventh edition. in Document M7-A7 Wayne, Pennsylvania 19087-1898, USA: Clinical Laboratory Standards Institute (CLSI), 940 West Valley Road, Suite 1400; 2007;
4. Clinical Laboratory Standards Institute . Performance standards for antimicrobial susceptibility testing. in Document M100-S19 Wayne, Pennsylvania 19087-1898, USA: Clinical Laboratory Standards Institute (CLSI), 940 West Valley Road, Suite 1400; 2009;
5. Tanaseanu C, Bergallo C, Teglia O, Jasovich A, Oliva ME, Dukart G, et al. on behalf of the 308 and 313 study groups Integrated results of two phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagnostic Microbiology and Infectious Disease. 2008;61:329–338
   • Abstract
   • Full Text
   • Full-Text PDF (331 KB)
   • CrossRef
6. Canadian Hospital Ward Antibiotic Resistance Surveillance (CANWARD) Study – 2007 . Canadian antimicrobial resistance alliance-CARA. Canadian Journal of Infectious Diseases and Medical Microbiology. 2009;20(Suppl. A):
7. Nicolau DP. Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. Expert Opinion on Pharmacotherapy. 2009;10(7):1213–1222
   • CrossRef